A nurse is planning care for a client who is experiencing opioid toxicity. Which of the following medications should the nurse anticipate administering?

A) "Inject the medication into the lateral thigh": While the lateral thigh is a common site for subcutaneous injections, enoxaparin is typically administered in the abdomen. Instructing the client to inject into the lateral thigh may lead to incorrect administration. Therefore, this instruction is not appropriate for enoxaparin administration.

B) "Ensure that the air bubble remains in the syringe": This instruction is correct. Enoxaparin prefilled syringes usually come with an air bubble to help ensure the full dose is delivered. Instructing the client to keep the air bubble in the syringe helps prevent the loss of medication during administration, ensuring that the full dose is delivered subcutaneously.

C) "Release the skin fold before injecting the medication": Releasing the skin fold before injecting the medication helps ensure proper needle insertion into the subcutaneous tissue and facilitates medication absorption. This instruction is generally appropriate for subcutaneous injections but is not specific to enoxaparin administration.

D) "Rub the site after injecting the medication": Rubbing the injection site after administration is not recommended, as it can cause irritation and discomfort. Instead, instruct the client to gently press on the injection site without rubbing to help disperse the medication and minimize bruising or discomfort. Therefore, this instruction is not appropriate for enoxaparin administration.

A) The client will wear his reading glasses when drawing up a dose of insulin glargine: This is the correct expected outcome. Older adults may experience visual changes that affect their ability to see clearly. Wearing reading glasses or using other visual aids can help ensure accurate measurement and administration of insulin glargine, reducing the risk of dosing errors.

B) The client will administer insulin glargine before each meal: This statement is incorrect. Insulin glargine is a long-acting insulin analog that is typically administered once daily at the same time each day, rather than before each meal. It provides a steady level of insulin over a 24-hour period and is not directly related to meal timing.

C) The client will use the deltoid muscle as an injection site: Using the deltoid muscle as an injection site for insulin glargine is not recommended. Insulin glargine is usually injected suIcutaneously into the abdomen, thigh, or upper arm. The deltoid muscle may not provide consistent absorption of insulin and is not commonly used for insulin injections.

D) The client will take an additional dose of insulin glargine prior to exercise: Taking an additional dose of insulin glargine prior to exercise is not a typical part of insulin glargine therapy. Adjustments to insulin doses for exercise should be made under the guidance of a healthcare provider, and additional doses of insulin glargine are not usually recommended for this purpose.